Eptinezumab (Vyepti) vs Galcanezumab (Emgality)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: CGRP ligand · full Migraine pipeline
Eptinezumab (Vyepti)
Marketed by H. Lundbeck
NCT02974153 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 1,121 participants. The hard clinical primary endpoint was met for both doses: monthly migraine days decreased by 8.2 days with 300 mg and 7.7 days with 100 mg versus 5.6 days with placebo, with both comparisons statistically significant (p<0.0001).
Next expected readout: March 2027 · NCT04965675 (registry estimate)
Reported efficacy
Change From Baseline in Monthly Migraine Days (Week 1-12): Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9) (met)
Result source: NCT02974153
Galcanezumab (Emgality)
Marketed by Eli Lilly and partners
NCT02614261 · Phase 3 · completed
The main treatment phase was a large, randomized, double-blind, placebo-controlled trial with 1,117 participants. Its clinical primary endpoint was met: both galcanezumab doses produced a statistically significant greater reduction in monthly migraine headache days than placebo.
Next expected readout: July 2031 · NCT07655440 (registry estimate)
Reported efficacy
Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. (Baseline, 3 Months): Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001. (met)
Result source: NCT03963232
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eptinezumab (Vyepti)'s landscape · Galcanezumab (Emgality)'s landscape